Market Cap : 2.31 B | Enterprise Value : 2.25 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
PTC Therapeutics Inc displays poor financial strength. Usually this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.PTC Therapeutics did not have earnings to cover the interest expense. PTC Therapeutics's debt to revenue ratio for the quarter that ended in Mar. 2022 was 0.89. As of today, PTC Therapeutics's Altman Z-Score is -1.26.
For the Biotechnology subindustry, PTC Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
PTC Therapeutics's Interest Expense for the months ended in Mar. 2022 was $-23.5 Mil. Its Operating Income for the months ended in Mar. 2022 was $-98.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $373.3 Mil.
PTC Therapeutics's Interest Coverage for the quarter that ended in Mar. 2022 is
PTC Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
PTC Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2022 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (158.862 | + | 373.283) | / | 594.94 | |
= | 0.89 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
PTC Therapeutics has a Z-score of -1.26, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -1.26 is in distress zone. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
PTC Therapeutics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Thank you for viewing the detailed overview of PTC Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Zacks 2022-02-18
By Seekingalpha 2022-01-12
By Zacks 2022-02-15
By Seekingalpha 2021-01-20
By Zacks 2021-10-28
By Seekingalpha 2021-02-26
By Zacks 2022-03-14
By Seekingalpha 2021-01-23
By Zacks 2020-08-18
By Zacks 2021-04-30
By Seekingalpha 2021-07-29
By Zacks 2022-02-22